Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Cornerstone Therapeutics Reports Second Quarter 2013 Financial Results


Cornerstone Therapeutics Reports Second Quarter 2013 Financial Results

CARY, NC -- (Marketwired) -- 08/06/13 -- Cornerstone Therapeutics Inc. (NASDAQ: CRTX)


 
--  Record net revenue for the second consecutive quarter, up 88% compared
    to the second quarter of 2012
--  Earnings per share of $0.19 vs. loss per share of $(0.17) in second
    quarter of 2012
--  Gross margin of 75%, compared to 59% in second quarter of 2012
--  CUROSURF(R) (poractant alfa) quarterly revenue hits all time high

Cornerstone Therapeutics Inc. (NASDAQ: CRTX), a specialty pharmaceutical company focused on commercializing products for the U.S. hospital and adjacent specialty markets, today announced results for the second quarter ended June 30, 2013.

Total net revenues were $40.4 million for the second quarter of 2013, compared to $21.5 million in the second quarter of 2012, an increase of 88%. CARDENE(R) I.V. (nicardipine hydrochloride) net sales were $14.2 million for the second quarter of 2013 compared to sales of $736,000 for the second quarter of 2012. The significant increase in sales is due primarily to the fact that sales for 2012 covered only the period after Cornerstone's acquisition of the product rights for CARDENE I.V. on June 26, 2012, as part of its acquisition of EKR Therapeutics, Inc. CUROSURF(R) net product sales totaled a record $11.3 million during the second quarter of 2013, representing an increase of 21% compared to the second quarter of 2012. Net sales of the ZYFLO(R) (zileuton) family of products amounted to $14.8 million for the second quarter of 2013, an increase of 37% over the second quarter of 2012.

Net income for the second quarter of 2013 was $5.8 million, or $0.19 per diluted share, compared to a net loss of $4.4 million, or $(0.17) per diluted share, in the second quarter of 2012. On a non-GAAP basis, net income for the second quarter was $9.9 million, or $0.33 per diluted share, up from $2.8 million, or $0.11 per diluted share, in the second quarter of 2012.

Non-GAAP net income and net income per diluted share exclude stock-based compensation expense, amortization of product rights, transaction-related expenses, acquisition adjustments related to inventory sold, the change in acquisition-related contingent payments and the gain on the divestiture of certain product rights.

"This was an impressive quarter for Cornerstone as we achieved record top-line results along with significant bottom-line growth of more than 130% compared to the first quarter of this year," said Craig A. Collard, Cornerstone's Chief Executive Officer. "Each of our products had a strong quarter, with CUROSURF in particular posting its highest quarterly revenues ever. In July, we initiated sales and marketing efforts for PERTZYE(R) (pancrelipase), which we anticipate will be followed by the launch of BETHKIS(R) (Tobramycin Inhalation Solution) later this year. As we continue to expand both the use of our currently marketed drugs as well as our overall product portfolio, we believe that this positive trajectory will continue."

A breakdown of net revenues by product for the three and six months ended June 30, 2013 (in thousands, except percentages) follows:


 
                                                                            
                                                                            
                Three Months                    Six Months                  
                   Ended                          Ended                     
                  June 30,        Change         June 30,         Change    
              --------------- -------------- --------------- ---------------
                2013    2012     $       %     2013    2012      $       %  
              ------- ------- ------- ------ ------- ------- -------- ------
Net product                                                                 
 sales                                                                      
 CARDENE I.V.                                                               
  product                                                                   
  family      $14,219 $   736 $13,483 1,832% $28,058 $   736 $ 27,322 3,712%
 CUROSURF      11,258   9,269   1,989     21  20,778  16,882    3,896     23
 ZYFLO product                                                              
  family       14,755  10,788   3,967     37  29,379  23,236    6,143     26
 Other                                                                      
  products        (4)     678   (682)     NM     (7)   2,774  (2,781)     NM
              ------- ------- -------        ------- ------- --------       
 Total net                                                                  
  product                                                                   
  sales        40,228  21,471  18,757     87  78,208  43,628   34,580     79
Other revenues    178       -     178     NM     178       4      174  4,350
              ------- ------- -------        ------- ------- --------       
Net revenues  $40,406 $21,471 $18,935     88 $78,386 $43,632 $ 34,754     80
              ======= ======= =======        ======= ======= ========       

Gross margin (exclusive of license and royalty agreement revenues and amortization of product rights) for the second quarter of 2013 was 75%, up from 59% in the comparable quarter of 2012. This sharp increase was primarily due to the addition of CARDENE I.V., as well as growth in net product sales resulting from price increases and lower estimated rates for certain sales allowances.

Selling, general and administrative expenses were $13.8 million during the second quarter of 2013, a 55% increase over $8.9 million in the comparable quarter of 2012. This was driven by increases in compensation, travel and other related employee benefits due to the continued growth of the company's products and related sales force. The increase is also due to greater advertising and promotional expenses related to CARDENE I.V., as well as support of the recent launch of PERTZYE and anticipated launch of BETHKIS.

As of June 30, 2013, Cornerstone had $55.5 million in cash and cash equivalents, a decrease of $0.7 million from December 31, 2012. The impact on cash was largely due to an upfront payment related to the license of PERTZYE of $10.0 million and contingent payments related to CARDENE of $2.6 million, offset by $12.1 million in cash generated by operating activities during the six months ending June 30, 2013.

Conference Call Information

Cornerstone Therapeutics will host a conference call today at 8:30 AM ET to discuss financial results for the three months ended June 30, 2013. To participate in the live conference call, please dial 888-539-3612 (U.S. callers) or 719-325-2484 (international callers), and provide passcode 6619268. A live webcast of the call will also be available through the Investor Relations section of the Company's website. Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The conference call and the webcast will be archived for 30 days. The telephone replay of the call will be available approximately two hours after completion of the call by dialing 888-203-1112 (U.S. callers) or 719-457-0820 (international callers), and providing passcode 6619268.

About Cornerstone Therapeutics

Co rnerstone Therapeutics Inc. (NASDAQ: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets. Key elements of the Company's strategy are to focus its commercial and development efforts in the hospital and adjacent specialty product sector within the U.S. pharmaceutical marketplace; continue to seek out opportunities to acquire companies, marketed or registration-stage products and late-stage development products that fit within the Company's focus areas; and generate revenues by marketing approved generic products through the Company's wholly-owned subsidiary, Aristos Pharmaceuticals, Inc. For more information, visit www.crtx.com.

Use of Non-GAAP Financial Measures

To supplement the consolidated financial statements presented in accordance with GAAP, the Company uses non-GAAP measures of certain components of financial performance. These non-GAAP measures include non-GAAP operating income, non-GAAP net income and non-GAAP net income per diluted share. The Company's management regularly uses supplemental non-GAAP financial measures to understand, manage and evaluate its business and make operating and compensation decisions. These non-GAAP measures are among the primary factors management uses in planning for and forecasting future periods.

These non-GAAP measures are not in accordance with, or an alternative to, measures prepared in accordance with GAAP and may be different from similarly titled non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. The additional non-GAAP financial information presented in this press release should be considered in conjunction with, and not as a substitute for, or superior to, the financial information presented in accordance with GAAP (such as operating income (loss), net income (loss) and earnings (loss) per share) and should not be considered measures of the Company's liquidity. These non-GAAP measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures.

The non-GAAP financial measures reflect adjustments for stock-based compensation expense, amortization of product rights, transaction-related expenses, acquisition adjustments related to inventory sold, changes in acquisition-related contingent payments and the gain on the divestiture of certain product rights. Transaction-related expenses consist of (1) costs incurred to complete product or company acquisitions or other strategic transactions, including due diligence and legal, consulting and other related fees; (2) integration costs related to the Company's completed transactions; and (3) transaction-related fees associated with transactions that are not consummated. The Company excludes these expenses from its non-GAAP measures because it believes that their exclusion provides an additional means to assess the extent to which the Company's efforts and execution of its strategy are reflected in its operating results. In particular, stock-based compensation expense is excluded primarily because it is a non-cash expense that is determined based on subjective assumptions; amortization of product rights is excluded because it is not reflective of the cash-settled expenses incurred related to product sales; and the transaction-related expenses, acquisition adjustments related to inventory sold, changes in acquisition contingent payments and the Company's gain on the divestiture of certain product rights are excluded because management believes they have no direct correlation to current operating results. Management believes that these non-GAAP measures, when shown in conjunction with the corresponding GAAP measures, enhance investors' and management's overall understanding of the Company's current financial performance and its prospects for the future.

The non-GAAP measures are subject to inherent limitations because (1) they do not reflect all of the expenses associated with the results of operations as determined in accordance with GAAP and (2) the exclusion of these expenses involves the exercise of judgment by management. Even though the Company has excluded stock-based compensation expense, amortization of product rights, transaction-related expenses, acquisition adjustments related to inventory sold, changes in acquisition-related contingent payments and the gain from the divestiture of product rights from the non-GAAP financial measures, stock-based compensation is an integral part of the Company's compensation structure, the acquisition of additional companies and/or product rights and the divestiture of the Company's anti-infective product rights are an important part of its business strategy and transaction-related expenses, whether or not the transaction is successfully closed, may be significant cash expenses.

Safe Harbor Statement

Statements in this press release regarding the progress and timing of our product development programs and related trials; our future opportunities; our strategy, future operations, anticipated financial position, future revenues and projected costs; our management's prospects, plans and objectives; and any other statements about management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Any statements that are not statements of historical fact (including, without limitation, statements containing the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "project," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements.

There are a number of important factors that could cause our actual results or events to differ materially from those indicated by such forward-looking statements, including risks relating to our "critical accounting estimates"; our ability to develop and maintain the necessary sales, marketing, supply chain, distribution and manufacturing capabilities to commercialize our products; patient, physician and third-party payer acceptance of our products as safe and effective therapeutic products; our heavy dependence on the commercial success of a relatively small number of currently marketed products; our ability to maintain regulatory approvals to market and sell our products; our ability to obtain U.S. Food and Drug Administration, or FDA, approval to manufacture, market and sell our products and product candidates, including RETAVASE(R) (Reteplase); our ability to successfully and effectively launch our Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended Release Suspension product and BETHKIS; our ability to enter into additional strategic licensing, product acquisition, collaboration or co-promotion transactions on favorable terms, if at all; our ability to manage and control unknown liabilities in connection with any acquisitions; our ability to successfully manage growth or integrate acquired businesses and operations; our ability to maintain compliance with NASDAQ listing requirements; adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including diffi culties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our product candidates and whether such results will be indicative of results obtained in later clinical trials; our ability to develop and commercialize our product candidates before our competitors develop and commercialize competing products; our ability to satisfy FDA and other regulatory requirements; our substantial indebtedness and debt covenants; and our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the SEC on March 14, 2013 and in our subsequent filings with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this press release reflect our expectations and beliefs only as of the date of this release. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as may be required by law. Our forward-looking statements do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this release.

Trademarks

ZYFLO(R) is a registered trademark of Cornerstone Therapeutics Inc. CARDENE(R) I.V. and RETAVASE(R) are registered trademarks of EKR Therapeutics, LLC, Cornerstone Therapeutics' wholly-owned subsidiary. CUROSURF(R) and BETHKIS(R) are owned by Chiesi Farmaceutici S.p.A. and licensed to Cornerstone Therapeutics for sales and marketing purposes in the United States. PERTZYE(R) is a registered trademark of Digestive Care, Inc. and licensed to Cornerstone Therapeutics for sales and marketing purposes in the United States.


 
                                                                            
                       CORNERSTONE THERAPEUTICS INC.                        
           CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)           
                                (UNAUDITED)                                 
              (In thousands, except share and per share data)               
                                                                            
                    Three Months Ended June 30,   Six Months Ended June 30, 
                    ---------------------------  -------------------------- 
                        2013           2012          2013          2012     
                    ------------   ------------  ------------  ------------ 
                                                                            
Net revenues        $     40,406   $     21,471  $     78,386  $     43,632 
Costs and expenses:                                                         
  Cost of product                                                           
   sales (exclusive                                                         
   of amortization                                                          
   of product                                                               
   rights)                10,105          8,901        22,262        17,587 
  Selling, general                                                          
   and                                                                      
   administrative         13,800          8,890        26,917        19,812 
  Research and                                                              
   development               615            686         1,442         1,731 
  Amortization of                                                           
   product rights          4,300          3,189         8,455         8,490 
  Change in                                                                 
   acquisition-                                                             
   related                                                                  
   contingent                                                               
   payments                1,384              -         3,782             - 
  Transaction-                                                              
   related expenses          454          5,438         1,137         6,180 
  Other operating                                                           
   expenses, net            (988)             -          (988)       (1,492)
                    ------------   ------------  ------------  ------------ 
    Total costs and                                                         
     expenses             29,670         27,104        63,007        52,308 
                    ------------   ------------  ------------  ------------ 
Income (loss) from                                                          
 operations               10,736         (5,633)       15,379        (8,676)
Other expenses, net:                                                        
  Interest expense,                                                         
   net                    (1,661)          (113)       (3,324)         (115)
  Other income, net            -              -           529             - 
                    ------------   ------------  ------------  ------------ 
    Total other                                                             
     expenses             (1,661)          (113)       (2,795)         (115)
                    ------------   ------------  ------------  ------------ 
                                                                            
Income (loss) before                                                        
 income taxes              9,075         (5,746)       12,584        (8,791)
(Provision for)                                                             
 benefit from income                                                        
 taxes                    (3,312)         1,393        (4,406)        2,613 
                    ------------   ------------  ------------  ------------ 
Net income (loss)   $      5,763   $     (4,353) $      8,178  $     (6,178)
                    ============   ============  ============  ============ 
                                                                            
Comprehensive income                                                        
 (loss)             $      5,763   $     (4,353) $      8,178  $     (6,178)
                    ============   ============  ============  ============ 
                                                                            
Net income (loss)                                                           
 per share, basic   $       0.22   $      (0.17) $       0.31  $      (0.24)
                    ============   ============  ============  ============ 
Net income (loss)                                                           
 per share, diluted $       0.19   $      (0.17) $       0.28  $      (0.24)
                    ============   ============  ============  ============ 
Weighted-average                                                            
 common shares,                                                             
 basic                26,459,463     26,058,941    26,412,014    25,937,656 
                    ============   ============  ============  ============ 
Weighted-average                                    
                        
 common shares,                                                             
 diluted              31,354,267     26,058,941    31,163,691    25,937,656 
                    ============   ============  ============  ============ 
                                                                            
                                                                            
                                                                            
                       CORNERSTONE THERAPEUTICS INC.                        
                        CONSOLIDATED BALANCE SHEETS                         
              (In thousands, except share and per share data)               
                                                                            
                                                   June 30,                 
                                                     2013      December 31, 
                                                  (Unaudited)      2012     
                                                 ------------  ------------ 
Assets                                                                      
Current assets:                                                             
  Cash and cash equivalents                      $     55,533  $     56,250 
  Accounts receivable, net                             21,912        14,368 
  Inventories, net                                     13,941        11,384 
  Prepaid expenses                                      4,434         3,343 
  Income tax receivable                                     -         4,094 
  Deferred tax asset                                    3,330         1,614 
  Acquisition-related current assets                    6,759        11,134 
  Other current assets                                    193           379 
                                                 ------------  ------------ 
    Total current assets                              106,102       102,566 
                                                 ------------  ------------ 
Property and equipment, net                             1,636         1,310 
Product rights, net                                   233,656       232,111 
Goodwill                                               33,151        33,356 
Other assets                                               32            32 
                                                 ------------  ------------ 
    Total assets                                 $    374,577  $    369,375 
                                                 ============  ============ 
                                                                            
Liabilities and Stockholders' Equity                                        
Current liabilities:                                                        
  Accounts payable                               $      6,247  $     12,439 
  Accrued expenses                                     39,861        37,379 
  Acquisition-related contingent payments               8,035         6,846 
  Acquisition-related current liabilities               6,697         9,636 
  Other current liabilities                             1,358           525 
                                                 ------------  ------------ 
    Total current liabilities                          62,198        66,825 
                                                 ------------  ------------ 
Acquisition-related contingent payments, less                               
 current portion                                       26,378        26,362 
Long-term debt                                         89,592        89,540 
Deferred tax liability                                 15,667        15,683 
Other long-term liabilities                             4,438         4,792 
                                                 ------------  ------------ 
    Total liabilities                                 198,273       203,202 
                                                 ------------  ------------ 
                                                                            
Stockholders' equity                                                        
  Preferred stock - $0.001 par value, 5,000,000                             
   shares authorized; no shares issued and                                  
   outstanding                                              -             - 
  Common stock - $0.001 par value, 90,000,000                               
   shares authorized; 26,497,738 and 26,348,470                             
   shares issued and outstanding as of June 30,                             
   2013 and December 31, 2012, respectively                26            26 
  Additional paid-in capital                          169,414       167,461 
  Retained earnings (accumulated deficit)               6,864        (1,314)
                                                 ------------  ------------ 
    Total stockholders' equity                        176,304       166,173 
                                                 ------------  ------------ 
    Total liabilities and stockholders' equity   $    374,577  $    369,375 
                                                 ============  ============ 
                                                                            
                                                                            
                                                                            
                       CORNERSTONE THERAPEUTICS INC.                        
                   CONSOLIDATED STATEMENTS OF CASH FLOWS                    
                                (UNAUDITED)                                 
                               (In thousands)                               
                                                  Six Months Ended June 30, 
                                                 -------------------------- 
                                                     2013          2012     
                                                 ------------  ------------ 
Cash flows from operating activities                                        
Net income (loss)                                $      8,178  $     (6,178)
Adjustments to reconcile net income (loss) to net                           
 cash provided by (used in) operating activities:                           
  Amortization and depreciation                         8,826         8,788 
  Amortization of debt costs                               52             - 
  Provision for prompt payment discounts                2,254         1,257 
  Provision for other receivables                          52             - 
  Provision for inventory allowances                    1,292           261 
  Acquisition accounting adjustment on inventory                            
   sold                                                    75           159 
  Gain on sale of product rights                            -        (1,492)
  Change in acquisition-related contingent                                  
   payments                                             3,782             - 
  Stock-based compensation                              1,390         1,343 
  Deferred revenue                                          -        (1,047)
  Deferred income taxes                                 2,026        (1,943)
Changes in operating assets and liabilities:                                
  Accounts receivable                                  (9,752)       (1,205)
  Inventories                                          (3,924)       (1,080)
  Prepaid expenses and other assets                    (1,213)        6,995 
  Accounts payable, accrued expenses, and other                             
   liabilities                                         (3,826)       (7,922)
  Acquisition-related current assets and                                    
   liabilities                                        
  1,571             - 
  Income taxes receivable                               1,324           209 
                                                 ------------  ------------ 
    Net cash provided by (used in) operating                                
     activities                                        12,107        (1,855)
                                                 ------------  ------------ 
                                                                            
Cash flows from investing activities                                        
Acquisition of businesses, net of cash acquired            13      (126,920)
Purchase of product rights                            (10,000)            - 
Purchase of property and equipment                       (697)          (99)
Proceeds from sale of product rights                        -         3,000 
                                                 ------------  ------------ 
    Net cash used in investing activities             (10,684)     (124,019)
                                                 ------------  ------------ 
                                                                            
Cash flows from financing activities                                        
Proceeds from term loans                                    -        90,000 
Proceeds of debt financing costs                            -          (511)
Proceeds from exercise of common stock options            567           818 
Excess tax benefit from stock-based compensation            3           256 
Payments related to net settlement of restricted                            
 stock                                                     (7)          (79)
Acquisition-related contingent payments                (2,644)            - 
Principal payments on capital lease obligation            (59)          (20)
                                                 ------------  ------------ 
    Net cash (used in) provided by financing                                
     activities                                        (2,140)       90,464 
                                                 ------------  ------------ 
    Net decrease in cash and cash equivalents            (717)      (35,410)
Cash and cash equivalents as of beginning of                                
 period                                                56,250        73,968 
                                                 ------------  ------------ 
Cash and cash equivalents as of end of period    $     55,533  $     38,558 
                                                 ============  ============ 
                                                                            
                                                                            
                                                                            
         CORNERSTONE THERAPEUTICS INC.                                      
 RECONCILIATION OF NON-GAAP FINANCIAL MEASURES                              
                                                                            
                                                                            
The following tables reconcile our non-GAAP measures to the most directly   
 comparable GAAP financial measures (in thousands, except share and per     
 share amounts):                                                            
                                                                            
                     For the Three Months Ended   For the Six Months Ended  
                              June 30,                    June 30,          
                     --------------------------  -------------------------- 
                         2013          2012          2013          2012     
                     ------------  ------------  ------------  ------------ 
GAAP income (loss)                                                          
 from operations     $     10,736  $     (5,633) $     15,379  $     (8,676)
  Add: stock-based                                                          
   compensation               722           668         1,390         1,343 
  Add: amortization                                                         
   of product rights        4,300         3,189         8,455         8,490 
  Add: transaction-                                                         
   related expenses           454         5,438         1,137         6,180 
  Add: acquisition                                                          
   adjustments                                                              
   related to                                                               
   inventory sold              46           159            75           159 
  Less: change in                                                           
   acquisition-                                                             
   related contingent                                                       
   payments                 1,384             -         3,782             - 
  Less: gain on                                                             
   divestiture of                                                           
   product rights               -             -             -        (1,492)
                     ------------  ------------  ------------  ------------ 
Non-GAAP income from                                                        
 operations          $     17,642  $      3,821  $     30,218  $      6,004 
                     ============  ============  ============  ============ 
                                                                            
GAAP net income                                                             
 (loss)              $      5,763  $     (4,353) $      8,178  $     (6,178)
  Add: stock-based                                                          
   compensation               722           668         1,390         1,343 
  Add: amortization                                                         
   of product rights        4,300         3,189         8,455         8,490 
  Add: transaction-                                                         
   related expenses           454         5,438         1,137         6,180 
  Add: acquisition                                                          
   adjustments                                                              
   related to                                                               
   inventory sold              46           159            75           159 
  Less: change in                                                           
   acquisition-                                                             
   related contingent                                                       
   payments                 1,384             -         3,782             - 
  Less: gain on                                                             
   divestiture of                                                           
   product rights               -             -             -        (1,492)
  Less: tax effects                                                         
   related to above                                                         
   items(1)                (2,745)       (2,292)       (5,987)       (4,363)
                     ------------  ------------  ------------  ------------ 
Non-GAAP net income  $      9,924  $      2,809  $     17,030  $      4,139 
                     ============  ============  ============  ============ 
                                                                            
GAAP net income                                                             
 (loss) per share,                                                          
 diluted             $       0.19  $      (0.17) $       0.28  $      (0.24)
                     ============  ============  ============  ============ 
Non-GAAP net income                                                         
 per share,                                                                 
 diluted(2)          $       0.33  $       0.11  $       0.57  $       0.16 
                     ============  ============  ============  ============ 
                                                                            
Shares used in                                                              
 diluted net income                                                         
 (loss) per share                                                           
 calculation:                                                               
  GAAP net income                                                           
   (loss)              31,354,267    26,058,941    31,163,691    25,937,656 
                     ============  ============  ============  ============ 
  Non-GAAP net income  31,354,267    26,693,195    31,163,691    26,492,610 
                     ============  ============  ============  ============ 
                                                                            
                                                                            
(1) Income taxes typically represent a complex element of our consolidated  
statement of comprehensive income (loss) and effective tax rates can vary   
widely between different periods. As such, for the three and six months     
ended June 30, 2013, we calculated non-GAAP net income by applying our      
statutory tax rate of 37.9% to non-GAAP income before taxes of $16.0        
million and $27.4 million, respectively. The tax effects for the three and  
six months ended June 30, 2013 represent the difference between our GAAP    
tax provision of $3.3 million and $4.4 million, respectively, and our       
calculated non-GAAP tax expense of $6.1 million and $10.4 million,          
respectively. Tax effects for the three and six months ended June 30, 2012  
were calculated using the effective tax rates of (24.2)% and (29.7)%,       
respectively.                                                               
                                                                            
(2) The convertible term loan was determined to be dilutive to non-GAAP net 
income per share, diluted for the three and six months ended June 30, 2013. 
As such, for the three and six months ended June 30, 2013, non-GAAP net     
income was adjusted for $311,000 and $619,000, respectively, of interest    
expense related to the convertible term loan, net of tax effects. Non-GAAP  
net income adjusted for the related interest expense, net of tax effects,   
was divided by the sum of the weighted-average number of common shares and  
dilutive common share equivalents outstanding during the period, as         
adjusted for the impact of the shares related to the convertible debt of    
approximately 4.2 million shares for both the three and six months ended    
June 30, 2013.                                                              

G-Q313-01

Contacts

Investor Relations Contact: Josh Franklin Vice President, Strategy and Business Development +1-919-678-6520 josh.franklin@crtx.com

Media Relations Contact: Fleishman-Hillard Andrea Moody +1-919-457-0743 andrea.moody@fleishman.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement